💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Venlafaxine

CHEMBL637 Phase 4 승인됨 Small molecule
Half-Life
5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
277.4 g/mol
LogP
2.9
Phase
4

This serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. It works by increasing the levels of serotonin and norepinephrine in the brain, which helps regulate mood and anxiety. Blood pressure should be monitored as it can cause small increases, particularly at higher doses.

분자량

277.4020 g/mol

LogP

2.90

TPSA

32.70 Ų

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Oncology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Major Depressive Disorder Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

약물 분류

N — N - Nervous System

작용 기전

Serotonin-norepinephrine reuptake inhibitor (SNRI).

Pharmacokinetics (PK)

Half-Life 5 hours

Pharmacodynamics (PD)

기전

Serotonin-norepinephrine reuptake inhibitor (SNRI).

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H27NO2

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
회전 가능 결합

                        
5

                    

                    
                    
                    

                        
무거운 원자

                        
20

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            SLC6A4 (Serotonin Transporter)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Venlafaxine + Tramadol
                            
                        

                        
                        
Venlafaxine and tramadol together pose a high risk of serotonin syndrome due to complementary serotonergic mechanisms.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Venlafaxine + Bupropion
                            
                        

                        
                        
Bupropion inhibits CYP2D6, significantly increasing venlafaxine plasma concentrations, which may enhance both therapeutic and adverse serotonergic effects.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Venlafaxine + Carbamazepine
                            
                        

                        
                        
Carbamazepine significantly reduces venlafaxine plasma concentrations through CYP3A4 induction, potentially reducing antidepressant efficacy.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. It works by increasing the levels of serotonin and norepinephrine in the brain, which helps regulate mood and anxiety. Blood pressure should be monitored as it can cause small increases, particularly at higher doses.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Serotonin-norepinephrine reuptake inhibitor (SNRI).

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Venlafaxine: Half-life: 5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Venlafaxine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL637.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5656.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.